ScreenerHero

DFTX Definium Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · definiumtx.com
35.09USD-1.49%Mkt Cap: 4.71B $P/E: —

Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap4.71B USD
Enterprise Value3.74B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-183.79M USD
Revenue/Share—
Last Price35.09 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees105
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-18.72
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B5.21
EPS (TTM)-3.37
EPS (Forward)-1.90
52W Range
9.53064% of range49.70
52W High49.70 USD
52W Low9.530 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-55.30%
ROA-41.76%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-131.56M USD
CapEx (TTM)—
FCF Margin—
FCF Yield0.16%
Net Debt-1.05B USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.12
Current Ratio6.95
Quick Ratio6.89
Book Value/Sh6.84 USD
Cash/Share8.07 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:15
Split DateAug 29, 2022
Analyst Consensus
Rating—
Target (Mean)71.65 USD
Upside (mean)+104.2%
Target Range55.00 USD – 91.00 USD
55.00+104.2% to mean91.00
# Analysts17
Ownership
Shares Out.134.37M
Float125.17M
Insiders2.57%
Institutions88.43%
Short Interest
Short Ratio5.8d
Short % Float8.83%
Short % Out.8.77%
Shares Short11.79M
Short (prev mo.)8.97M
Technical
SMA 5040.99 (-14.4%)
SMA 20027.53 (+27.5%)
Beta2.19
S&P 52W Chg16.45%
Avg Vol (30d)2.13M
Avg Vol (10d)2.31M
Technical Indicators
RSI (14)37.3
MACD-1.2455
MACD Signal-1.0823
MACD Hist.-0.1632
BB Upper40.57 USD
BB Middle37.77 USD
BB Lower34.98 USD
BB Width14.80%
ATR (14)2.072 USD
Vol Ratio (20d)0.84x